GPR35; ADRA2C; ADRA2A; DRD4; | |
NPSR1; CXCR1; NMUR2; | |
ALPI; RECQL; PLA2G1B; TDP1; BLM; CTDSP1; P4HB; PIK3R1; GLO1; HPGD; MPO; HSD17B1; AKR1B1; HSD17B2; HSD17B10; ALOX15; ALDH1A1; ALOX12; NOX4; USP2; PYGL; APEX1; POLB; | |
ACHE; GAA; | |
DUSP3; | |
NEK6; AKT1; MET; GSK3B; CSNK2A1; DAPK1; AXL; NEK2; FLT3; CAMK2B; SRC; IGF1R; PTK2; BRAF; AURKB; AURKA; FLT4; EPHB4; MAP3K8; TEK; PDGFRB; INSR; PLK4; CDK1; MAPK1; EGFR; ERBB2; PIM1; NUAK1; ALK; KDR; PLK1; PKN1; | |
CA7; CA5A; CA3; CA14; CA5B; CA12; CA9; CA13; CA4; CA6; CA2; CA1; | |
AR; | |
ESRRA; | |
KDM4E; | |
MAOA; ALOX5; TYR; XDH; | |
MMP13; MMP3; MMP2; MMP9; | |
BACE1; | |
AHR; STAT6; HIF1A; NFKB1; TP53; | |
FUT7; | |
ABCC1; ABCG2; | |
SLC22A6; | |
SMAD3; LMNA; MAPT; HBB; HSPA1A; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Aspartic protease | BACE1 | Beta-secretase 1 | P56817 | CHEMBL4822 |
ATP-binding cassette | ABCC1 | Multidrug resistance-associated protein 1 | P33527 | CHEMBL3004 |
ATP-binding cassette | ABCG2 | ATP-binding cassette sub-family G member 2 | Q9UNQ0 | CHEMBL5393 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Cytochrome P450 family 2 | CYP2C8 | Cytochrome P450 2C8 | P10632 | CHEMBL3721 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | HPGD | 15-hydroxyprostaglandin dehydrogenase [NAD+] | P15428 | CHEMBL1293255 |
Enzyme_unclassified | MPO | Myeloperoxidase | P05164 | CHEMBL2439 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | HSD17B2 | Estradiol 17-beta-dehydrogenase 2 | P37059 | CHEMBL2789 |
Enzyme_unclassified | HSD17B10 | Endoplasmic reticulum-associated amyloid beta-peptide-binding protein | Q99714 | CHEMBL4159 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | ALDH1A1 | Aldehyde dehydrogenase 1A1 | P00352 | CHEMBL3577 |
Enzyme_unclassified | ALOX12 | Arachidonate 12-lipoxygenase | P18054 | CHEMBL3687 |
Enzyme_unclassified | NOX4 | NADPH oxidase 4 | Q9NPH5 | CHEMBL1250375 |
Enzyme_unclassified | USP2 | Ubiquitin carboxyl-terminal hydrolase 2 | O75604 | CHEMBL1293227 |
Enzyme_unclassified | PYGL | Liver glycogen phosphorylase | P06737 | CHEMBL2568 |
Enzyme_unclassified | APEX1 | DNA-(apurinic or apyrimidinic site) lyase | P27695 | CHEMBL5619 |
Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
Enzyme_unclassified | ALPI | Intestinal alkaline phosphatase | P09923 | CHEMBL5573 |
Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | CTDSP1 | Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 1 | Q9GZU7 | CHEMBL1795098 |
Enzyme_unclassified | P4HB | Protein disulfide-isomerase | P07237 | CHEMBL5422 |
Enzyme_unclassified | PIK3R1 | PI3-kinase p85-alpha subunit | P27986 | CHEMBL2506 |
Enzyme_unclassified | GLO1 | Glyoxalase I | Q04760 | CHEMBL2424 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Hydrolase | GAA | Lysosomal alpha-glucosidase | P10253 | CHEMBL2608 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA13 | Carbonic anhydrase XIII | Q8N1Q1 | CHEMBL3912 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Lyase | CA2 | Carbonic anhydrase II | P00918 | CHEMBL205 |
Lyase | CA1 | Carbonic anhydrase I | P00915 | CHEMBL261 |
Lysine demethylase | KDM4E | Lysine-specific demethylase 4D-like | B2RXH2 | CHEMBL1293226 |
Metallo protease | MMP13 | Matrix metalloproteinase 13 | P45452 | CHEMBL280 |
Metallo protease | MMP3 | Matrix metalloproteinase 3 | P08254 | CHEMBL283 |
Metallo protease | MMP2 | Matrix metalloproteinase-2 | P08253 | CHEMBL333 |
Metallo protease | MMP9 | Matrix metalloproteinase 9 | P14780 | CHEMBL321 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Nuclear hormone receptor subfamily 3 group C | AR | Androgen Receptor | P10275 | CHEMBL1871 |
Oxidoreductase | MAOA | Monoamine oxidase A | P21397 | CHEMBL1951 |
Oxidoreductase | ALOX5 | Arachidonate 5-lipoxygenase | P09917 | CHEMBL215 |
Oxidoreductase | TYR | Tyrosinase | P14679 | CHEMBL1973 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Peptide receptor (family A GPCR) | NPSR1 | Neuropeptide S receptor | Q6W5P4 | CHEMBL5162 |
Peptide receptor (family A GPCR) | CXCR1 | Interleukin-8 receptor A | P25024 | CHEMBL4029 |
Peptide receptor (family A GPCR) | NMUR2 | Neuromedin-U receptor 2 | Q9GZQ4 | CHEMBL1075144 |
Protein Kinase | NEK6 | Serine/threonine-protein kinase NEK6 | Q9HC98 | CHEMBL4309 |
Protein Kinase | AKT1 | Serine/threonine-protein kinase AKT | P31749 | CHEMBL4282 |
Protein Kinase | MET | Hepatocyte growth factor receptor | P08581 | CHEMBL3717 |
Protein Kinase | GSK3B | Glycogen synthase kinase-3 beta | P49841 | CHEMBL262 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Protein Kinase | DAPK1 | Death-associated protein kinase 1 | P53355 | CHEMBL2558 |
Protein Kinase | AXL | Tyrosine-protein kinase receptor UFO | P30530 | CHEMBL4895 |
Protein Kinase | NEK2 | Serine/threonine-protein kinase NEK2 | P51955 | CHEMBL3835 |
Protein Kinase | FLT3 | Tyrosine-protein kinase receptor FLT3 | P36888 | CHEMBL1974 |
Protein Kinase | CAMK2B | CaM kinase II beta | Q13554 | CHEMBL4121 |
Protein Kinase | SRC | Tyrosine-protein kinase SRC | P12931 | CHEMBL267 |
Protein Kinase | IGF1R | Insulin-like growth factor I receptor | P08069 | CHEMBL1957 |
Protein Kinase | PTK2 | Focal adhesion kinase 1 | Q05397 | CHEMBL2695 |
Protein Kinase | BRAF | Serine/threonine-protein kinase B-raf | P15056 | CHEMBL5145 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | FLT4 | Vascular endothelial growth factor receptor 3 | P35916 | CHEMBL1955 |
Protein Kinase | EPHB4 | Ephrin type-B receptor 4 | P54760 | CHEMBL5147 |
Protein Kinase | MAP3K8 | Mitogen-activated protein kinase kinase kinase 8 | P41279 | CHEMBL4899 |
Protein Kinase | TEK | Tyrosine-protein kinase TIE-2 | Q02763 | CHEMBL4128 |
Protein Kinase | PDGFRB | Platelet-derived growth factor receptor beta | P09619 | CHEMBL1913 |
Protein Kinase | INSR | Insulin receptor | P06213 | CHEMBL1981 |
Protein Kinase | PLK4 | Serine/threonine-protein kinase PLK4 | O00444 | CHEMBL3788 |
Protein Kinase | CDK1 | Cyclin-dependent kinase 1 | P06493 | CHEMBL308 |
Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | ERBB2 | Receptor protein-tyrosine kinase erbB-2 | P04626 | CHEMBL1824 |
Protein Kinase | PIM1 | Serine/threonine-protein kinase PIM1 | P11309 | CHEMBL2147 |
Protein Kinase | NUAK1 | NUAK family SNF1-like kinase 1 | O60285 | CHEMBL5784 |
Protein Kinase | ALK | ALK tyrosine kinase receptor | Q9UM73 | CHEMBL4247 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | PLK1 | Serine/threonine-protein kinase PLK1 | P53350 | CHEMBL3024 |
Protein Kinase | PKN1 | Protein kinase N1 | Q16512 | CHEMBL3384 |
Protein Phosphatase | DUSP3 | Dual specificity protein phosphatase 3 | P51452 | CHEMBL2635 |
SLC superfamily of solute carriers | SLC22A6 | Solute carrier family 22 member 6 | Q4U2R8 | CHEMBL1641347 |
Small molecule receptor (family A GPCR) | GPR35 | G-protein coupled receptor 35 | Q9HC97 | CHEMBL1293267 |
Small molecule receptor (family A GPCR) | ADRA2C | Alpha-2c adrenergic receptor | P18825 | CHEMBL1916 |
Small molecule receptor (family A GPCR) | ADRA2A | Alpha-2a adrenergic receptor | P08913 | CHEMBL1867 |
Small molecule receptor (family A GPCR) | DRD4 | Dopamine D4 receptor | P21917 | CHEMBL219 |
Transcription Factor | AHR | Aryl hydrocarbon receptor | P35869 | CHEMBL3201 |
Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
Transferase | FUT7 | Alpha-(1,3)-fucosyltransferase 7 | Q11130 | CHEMBL3596077 |
Unclassified | SMAD3 | Mothers against decapentaplegic homolog 3 | P84022 | CHEMBL1293258 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Unclassified | HBB | Hemoglobin beta chain | P68871 | CHEMBL4331 |
Unclassified | HSPA1A | Heat shock 70 kDa protein 1 | P0DMV8 | CHEMBL5460 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 7.622E-12 | 1.418E-09 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.113E-11 | 1.900E-09 | ALOX12, ALOX15, ALOX5, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, XDH |
MF | GO:0005488; binding | GO:0020037; heme binding | 1.323E-11 | 2.216E-09 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, MPO, NOX4, SRC |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.151E-09 | 1.424E-07 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
BP | GO:0009987; cellular process | GO:0051897; positive regulation of protein kinase B signaling | 1.598E-09 | 1.891E-07 | AXL, EGFR, ERBB2, INSR, MET, NOX4, PDGFRB, PIK3R1, PTK2, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.868E-09 | 2.199E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9 |
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 1.891E-09 | 2.214E-07 | ALPI, AR, BLM, CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESRRA, GLO1, MMP13, MMP2, MMP3, MMP9, SMAD3, TP53 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 3.442E-09 | 3.883E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.023E-09 | 5.496E-07 | CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0019901; protein kinase binding | 7.908E-09 | 8.441E-07 | ADRA2A, AKT1, AURKA, BRAF, DUSP3, EGFR, GSK3B, HIF1A, MAPK1, NEK6, PDGFRB, PIK3R1, PKN1, PLK1, PTK2, SMAD3, SRC, TP53 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.710E-08 | 1.740E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
MF | Unclassified; | GO:0004716; signal transducer, downstream of receptor, with protein tyrosine kinase activity | 1.417E-07 | 1.254E-05 | EGFR, ERBB2, INSR, KDR |
CC | GO:0016020; membrane | GO:0016323; basolateral plasma membrane | 1.540E-07 | 1.347E-05 | ABCC1, ADRA2A, CA2, CA4, CA9, EGFR, ERBB2, HPGD, SLC22A6, TEK |
MF | GO:0005488; binding | GO:0046982; protein heterodimerization activity | 2.341E-07 | 1.976E-05 | ADRA2A, ADRA2C, AHR, AURKA, AXL, BRAF, EGFR, ERBB2, HIF1A, NFKB1, P4HB, PIK3R1, SMAD3, TP53, TYR |
CC | GO:0044464; cell part | GO:0005829; cytosol | 3.158E-07 | 2.615E-05 | AHR, AKR1B1, AKT1, ALDH1A1, ALOX12, ALOX15, ALOX5, AR, AURKA, AURKB, BLM, BRAF, CA1, CA13, CA2, CA3, CA7, CAMK2B, CDK1, CSNK2A1, DUSP3, EPHB4, ERBB2, FLT3, GLO1, GSK3B, HBB, HIF1A, HPGD, HSD17B1, HSPA1A, LMNA, MAP3K8, MAPK1, MAPT, NEK2, NEK6, NFKB1, PIK3R1, PIM1, PKN1, PLA2G1B, PLK1, PLK4, PTK2, PYGL, SMAD3, SMN1, SMN2, SRC, STAT6, TP53, TYR, XDH |
BP | GO:0008152; metabolic process | GO:0038083; peptidyl-tyrosine autophosphorylation | 3.263E-07 | 2.681E-05 | EGFR, IGF1R, INSR, KDR, PTK2, SRC |
BP | GO:0008152; metabolic process | GO:0018107; peptidyl-threonine phosphorylation | 3.873E-07 | 3.117E-05 | AKT1, CAMK2B, CDK1, CSNK2A1, GSK3B, MAPK1, PKN1 |
BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.492E-07 | 4.349E-05 | CYP1A2, CYP2C8, CYP2C9, CYP3A4 |
MF | GO:0005488; binding | GO:0043548; phosphatidylinositol 3-kinase binding | 6.952E-07 | 5.368E-05 | AXL, IGF1R, INSR, PDGFRB, PIK3R1 |
BP | GO:0008152; metabolic process | GO:0043552; positive regulation of phosphatidylinositol 3-kinase activity | 8.303E-07 | 6.235E-05 | FLT3, PDGFRB, PTK2, SRC, TEK |
BP | GO:0009987; cellular process | GO:0071276; cellular response to cadmium ion | 9.854E-07 | 7.273E-05 | AKT1, CYP1A2, EGFR, MAPK1, MMP9 |
BP | GO:0008152; metabolic process | GO:0006691; leukotriene metabolic process | 9.854E-07 | 7.273E-05 | ABCC1, ALOX12, ALOX15, ALOX5, PLA2G1B |
MF | GO:0005488; binding | GO:0019838; growth factor binding | 1.026E-06 | 7.522E-05 | EGFR, ERBB2, FLT4, IGF1R, INSR, KDR, PDGFRB, TEK |
BP | GO:0032502; developmental process | GO:0051094; positive regulation of developmental process | 1.126E-06 | 8.180E-05 | ADRA2C, AKT1, ALOX12, AR, AURKA, AXL, BRAF, CA2, CAMK2B, CDK1, CYP1B1, HIF1A, INSR, KDR, LMNA, MAPT, NFKB1, PDGFRB, PIM1, SMAD3, SRC, STAT6, TEK |
BP | GO:0032502; developmental process | GO:0007568; aging | 1.132E-06 | 8.186E-05 | AKT1, APEX1, AURKB, CDK1, CYP1A1, MPO, NOX4, PDGFRB, POLB, TP53 |
MF | GO:0005488; binding | GO:0051879; Hsp90 protein binding | 1.162E-06 | 8.353E-05 | AHR, CSNK2A1, HIF1A, KDR, MAPT |
BP | GO:0009987; cellular process | GO:0038084; vascular endothelial growth factor signaling pathway | 1.494E-06 | 1.053E-04 | FLT3, FLT4, KDR, PDGFRB |
BP | GO:0009987; cellular process | GO:0070301; cellular response to hydrogen peroxide | 1.578E-06 | 1.101E-04 | AKR1B1, APEX1, AXL, CDK1, CYP1B1, STAT6 |
BP | GO:0065007; biological regulation | GO:0032148; activation of protein kinase B activity | 1.591E-06 | 1.105E-04 | ADRA2A, ADRA2C, AKT1, INSR, SRC |
BP | GO:0008152; metabolic process | GO:0019372; lipoxygenase pathway | 1.983E-06 | 1.342E-04 | ALOX12, ALOX15, ALOX5, HPGD |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 1.985E-06 | 1.342E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0045931; positive regulation of mitotic cell cycle | 2.220E-06 | 1.481E-04 | APEX1, AURKA, CDK1, CYP1A1, DUSP3, INSR, PDGFRB, USP2 |
BP | GO:0009987; cellular process | GO:0070374; positive regulation of ERK1 and ERK2 cascade | 2.562E-06 | 1.680E-04 | ALOX15, BRAF, EGFR, FLT4, KDR, NOX4, PDGFRB, SRC, TEK |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 3.953E-06 | 2.473E-04 | CYP1A1, CYP2C8, CYP3A4 |
BP | GO:0009987; cellular process | GO:0030168; platelet activation | 3.995E-06 | 2.492E-04 | ADRA2A, ADRA2C, AKT1, AXL, MAPK1, PIK3R1, SRC |
BP | GO:0008152; metabolic process | GO:0045429; positive regulation of nitric oxide biosynthetic process | 4.146E-06 | 2.565E-04 | AKT1, EGFR, HBB, INSR, SMAD3 |
MF | GO:0005488; binding | GO:0042803; protein homodimerization activity | 4.142E-06 | 2.565E-04 | ABCG2, ACHE, ADRA2A, ADRA2C, AKT1, BLM, CAMK2B, FLT3, FLT4, HPGD, MAPT, NFKB1, PYGL, SLC22A6, SMAD3, TYR, XDH |
BP | GO:0032501; multicellular organismal process | GO:2000026; regulation of multicellular organismal development | 4.186E-06 | 2.582E-04 | ADRA2C, AKT1, ALOX12, AR, AXL, BRAF, CA2, CAMK2B, CDK1, CTDSP1, CYP1B1, EGFR, ERBB2, ESRRA, GSK3B, HIF1A, INSR, KDR, MAPT, PDGFRB, PIK3R1, PIM1, PTK2, SMAD3, SRC, STAT6, TEK, XDH |
BP | GO:0009987; cellular process | GO:0048010; vascular endothelial growth factor receptor signaling pathway | 4.212E-06 | 2.584E-04 | AXL, FLT4, KDR, PIK3R1, PTK2, SRC |
BP | GO:0009987; cellular process | GO:0070507; regulation of microtubule cytoskeleton organization | 4.645E-06 | 2.810E-04 | AURKA, GSK3B, HSPA1A, MAPT, MET, NEK2, PLK1, PLK4 |
BP | GO:0050896; response to stimulus | GO:0042060; wound healing | 6.241E-06 | 3.624E-04 | ALOX15, EGFR, ERBB2, PDGFRB, SMAD3, TP53 |
BP | GO:0050896; response to stimulus | GO:0055093; response to hyperoxia | 6.373E-06 | 3.691E-04 | CYP1A1, PDGFRB, POLB, TP53 |
CC | GO:0043226; organelle | GO:0005654; nucleoplasm | 6.717E-06 | 3.879E-04 | AHR, AKR1B1, AKT1, ALOX5, APEX1, AR, AURKA, AURKB, BLM, CAMK2B, CDK1, CSNK2A1, CTDSP1, DUSP3, ESRRA, GSK3B, HIF1A, HPGD, HSPA1A, LMNA, MAPK1, NEK2, NEK6, NFKB1, NUAK1, PIM1, PKN1, PLK1, POLB, RECQL, SMAD3, SMN1, SMN2, SRC, STAT6, TP53, USP2 |
MF | GO:0060089; molecular transducer activity | GO:0005021; vascular endothelial growth factor-activated receptor activity | 6.888E-06 | 3.957E-04 | FLT3, FLT4, KDR |
BP | Unclassified; | GO:0032846; positive regulation of homeostatic process | 7.835E-06 | 4.443E-04 | AURKB, CA2, CA7, EGFR, HIF1A, MAPK1, NEK2, NPSR1, PLA2G1B |
MF | Unclassified; | GO:0004872; receptor activity | 1.066E-05 | 5.905E-04 | ADRA2A, ADRA2C, AHR, ALK, AR, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, ESRRA, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPSR1, PDGFRB, TEK |
MF | GO:0005488; binding | GO:0051379; epinephrine binding | 1.097E-05 | 6.049E-04 | ADRA2A, ADRA2C, DRD4 |
BP | GO:0051179; localization | GO:0046903; secretion | 1.117E-05 | 6.078E-04 | ALOX5, AXL, CA2, CA9, CXCR1, DRD4, GAA, HBB, HIF1A, HSPA1A, MAPK1, MMP9, MPO, NFKB1, NMUR2, PLA2G1B, PYGL, SLC22A6, XDH |
MF | Unclassified; | GO:0099600; transmembrane receptor activity | 1.265E-05 | 6.784E-04 | ADRA2A, ADRA2C, ALK, AXL, CXCR1, DRD4, EGFR, EPHB4, ERBB2, FLT3, FLT4, GPR35, HPGD, IGF1R, INSR, KDR, MET, NMUR2, NPSR1, PDGFRB, TEK |
CC | GO:0043226; organelle | GO:0005876; spindle microtubule | 1.501E-05 | 7.990E-04 | AURKA, AURKB, CDK1, PLK1, POLB |
BP | GO:0009987; cellular process | GO:0000733; DNA strand renaturation | 1.639E-05 | 8.658E-04 | BLM, RECQL, TP53 |
BP | GO:0008152; metabolic process | GO:0045740; positive regulation of DNA replication | 1.802E-05 | 9.434E-04 | CDK1, EGFR, IGF1R, INSR, PLA2G1B |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 4.412E-25 | 4.443E-21 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0050896; response to stimulus | GO:0001101; response to acid chemical | 2.121E-05 | 1.087E-03 | AKR1B1, AKT1, EGFR, HSD17B2, KDR, MMP2, PDGFRB, SLC22A6, SRC, TP53 |
BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 2.237E-05 | 1.133E-03 | ALK, CDK1, DRD4, INSR, MAPK1, PKN1, PLA2G1B |
BP | Unclassified; | GO:0032844; regulation of homeostatic process | 2.430E-05 | 1.213E-03 | ADRA2A, AURKB, CA2, CA7, EGFR, HIF1A, KDR, MAPK1, NEK2, NPSR1, PLA2G1B, SRC |
BP | GO:0065007; biological regulation | GO:0098771; inorganic ion homeostasis | 2.590E-05 | 1.276E-03 | ABCG2, CA12, CA2, CA7, DRD4, EGFR, GPR35, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, SMAD3, TP53 |
MF | GO:0005488; binding | GO:0043560; insulin receptor substrate binding | 3.192E-05 | 1.517E-03 | IGF1R, INSR, PIK3R1 |
BP | GO:0009987; cellular process | GO:2001237; negative regulation of extrinsic apoptotic signaling pathway | 3.324E-05 | 1.573E-03 | AKT1, AR, DAPK1, HSPA1A, LMNA, SRC |
BP | GO:0065007; biological regulation | GO:0043006; activation of phospholipase A2 activity by calcium-mediated signaling | 3.453E-05 | 1.611E-03 | EGFR, NMUR2 |
BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 3.453E-05 | 1.611E-03 | APEX1, POLB |
BP | GO:0008152; metabolic process | GO:2001303; lipoxin A4 biosynthetic process | 3.453E-05 | 1.611E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0047977; hepoxilin-epoxide hydrolase activity | 3.453E-05 | 1.611E-03 | ALOX12, ALOX15 |
BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.510E-05 | 1.633E-03 | AKT1, HIF1A, LMNA, P4HB, SRC, TP53 |
BP | GO:0009987; cellular process | GO:0090068; positive regulation of cell cycle process | 3.607E-05 | 1.675E-03 | APEX1, AURKA, AURKB, CDK1, CYP1A1, INSR, PDGFRB, PLK4, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0003007; heart morphogenesis | 3.642E-05 | 1.680E-03 | EPHB4, GAA, INSR, PTK2 |
BP | Unclassified; | GO:0044236; multicellular organism metabolic process | 3.909E-05 | 1.785E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0014068; positive regulation of phosphatidylinositol 3-kinase signaling | 4.397E-05 | 1.958E-03 | FLT3, KDR, PDGFRB, PTK2, TEK |
MF | GO:0003824; catalytic activity | GO:0046934; phosphatidylinositol-4,5-bisphosphate 3-kinase activity | 4.397E-05 | 1.958E-03 | EGFR, ERBB2, MET, PDGFRB, PIK3R1 |
BP | GO:0065007; biological regulation | GO:0042593; glucose homeostasis | 4.416E-05 | 1.958E-03 | ADRA2A, AKT1, HIF1A, INSR, NOX4, PIK3R1, PYGL |
BP | GO:0008152; metabolic process | GO:0045913; positive regulation of carbohydrate metabolic process | 5.081E-05 | 2.222E-03 | AKT1, HIF1A, INSR, NFKB1, SRC |
BP | GO:0008152; metabolic process | GO:0006703; estrogen biosynthetic process | 5.485E-05 | 2.379E-03 | CYP19A1, HSD17B1, HSD17B2 |
BP | GO:0009987; cellular process | GO:0031334; positive regulation of protein complex assembly | 5.710E-05 | 2.472E-03 | ALOX15, GSK3B, HSPA1A, MAPT, MET, MMP3, SRC, TP53 |
MF | GO:0005488; binding | GO:0002039; p53 binding | 5.845E-05 | 2.510E-03 | BLM, GSK3B, HIF1A, NUAK1, TP53 |
BP | GO:0032501; multicellular organismal process | GO:0001503; ossification | 5.882E-05 | 2.516E-03 | ALOX15, EGFR, MMP13, MMP2, MMP9, TEK |
BP | GO:0009987; cellular process | GO:0043065; positive regulation of apoptotic process | 6.173E-05 | 2.630E-03 | AKT1, CYP1B1, DAPK1, GSK3B, HPGD, MAPT, MMP9, NOX4, PDGFRB, SMAD3, SRC, TP53, XDH |
BP | GO:0050896; response to stimulus | GO:0034405; response to fluid shear stress | 6.539E-05 | 2.749E-03 | AKT1, CA2, PDGFRB, SRC |
MF | Unclassified; | GO:0032403; protein complex binding | 6.770E-05 | 2.829E-03 | ACHE, ADRA2A, APEX1, EGFR, FLT3, IGF1R, INSR, KDR, MMP13, MMP9, P4HB, PIK3R1, PLK1, SMAD3, SRC |
BP | Unclassified; | GO:0006461; protein complex assembly | 7.051E-05 | 2.930E-03 | ACHE, AR, BLM, BRAF, CDK1, GSK3B, HBB, HSD17B10, HSPA1A, IGF1R, INSR, MAPT, PTK2, SLC22A6, SMAD3, SRC, TEK, TP53 |
BP | Unclassified; | GO:0044243; multicellular organismal catabolic process | 7.152E-05 | 2.950E-03 | MMP13, MMP2, MMP3, MMP9, PLA2G1B |
BP | GO:0009987; cellular process | GO:0038128; ERBB2 signaling pathway | 8.070E-05 | 3.266E-03 | EGFR, ERBB2, PIK3R1, SRC |
BP | GO:0023052; signaling | GO:0050806; positive regulation of synaptic transmission | 8.198E-05 | 3.306E-03 | BRAF, CA2, CA7, DRD4, EGFR, MAPK1 |
BP | GO:0007610; behavior | GO:0007610; behavior | 8.364E-05 | 3.366E-03 | ALK, BRAF, DRD4, EGFR, GAA, HIF1A, INSR, MAPK1, MAPT, NMUR2, TP53, USP2 |
BP | GO:0009987; cellular process | GO:1901796; regulation of signal transduction by p53 class mediator | 8.392E-05 | 3.371E-03 | AKT1, AURKA, AURKB, BLM, CSNK2A1, NUAK1, TP53 |
BP | GO:0009987; cellular process | GO:1900034; regulation of cellular response to heat | 9.820E-05 | 3.888E-03 | CAMK2B, GSK3B, HSPA1A, MAPK1, MAPT |
BP | GO:0009987; cellular process | GO:0032849; positive regulation of cellular pH reduction | 1.032E-04 | 4.019E-03 | CA2, CA7 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.032E-04 | 4.019E-03 | CYP1A1, CYP3A4 |
MF | GO:0003824; catalytic activity | GO:0004052; arachidonate 12-lipoxygenase activity | 1.032E-04 | 4.019E-03 | ALOX12, ALOX15 |
MF | GO:0060089; molecular transducer activity | GO:0004938; alpha2-adrenergic receptor activity | 1.032E-04 | 4.019E-03 | ADRA2A, ADRA2C |
MF | GO:0003824; catalytic activity | GO:0051120; hepoxilin A3 synthase activity | 1.032E-04 | 4.019E-03 | ALOX12, ALOX15 |
MF | GO:0003824; catalytic activity | GO:0004712; protein serine/threonine/tyrosine kinase activity | 1.083E-04 | 4.205E-03 | AKT1, AURKA, AURKB, MAPK1 |
BP | GO:0065007; biological regulation | GO:0031647; regulation of protein stability | 1.157E-04 | 4.468E-03 | AURKA, HSPA1A, MAPK1, PIK3R1, PLK1, SMAD3, SRC, USP2 |
BP | GO:0008152; metabolic process | GO:0032436; positive regulation of proteasomal ubiquitin-dependent protein catabolic process | 1.175E-04 | 4.505E-03 | AKT1, AURKA, GSK3B, HSPA1A, PLK1 |
BP | GO:0050896; response to stimulus | GO:1901655; cellular response to ketone | 1.175E-04 | 4.505E-03 | AKR1B1, AKT1, AR, EGFR, SRC |
CC | GO:0032991; macromolecular complex | GO:0043235; receptor complex | 1.244E-04 | 4.725E-03 | ABCG2, ADRA2A, AHR, EGFR, ERBB2, FLT4, IGF1R, INSR, SMAD3 |
BP | GO:0065007; biological regulation | GO:1904355; positive regulation of telomere capping | 1.282E-04 | 4.829E-03 | AURKB, MAPK1, NEK2 |
MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.282E-04 | 4.829E-03 | CYP2C19, CYP2C8, CYP2C9 |
BP | GO:0009987; cellular process | GO:0007077; mitotic nuclear envelope disassembly | 1.302E-04 | 4.897E-03 | CDK1, LMNA, NEK6, PLK1 |
BP | GO:0065007; biological regulation | GO:0030003; cellular cation homeostasis | 1.323E-04 | 4.967E-03 | ABCG2, CA2, CA7, DRD4, GPR35, HIF1A, MAPK1, NMUR2, NPSR1, PLA2G1B, SMAD3, TP53 |
BP | GO:0009987; cellular process | GO:0090199; regulation of release of cytochrome c from mitochondria | 1.423E-04 | 5.295E-03 | AKT1, LMNA, MMP9, TP53 |
BP | GO:0008283; cell proliferation | GO:0001938; positive regulation of endothelial cell proliferation | 1.560E-04 | 5.701E-03 | AKT1, FLT4, HIF1A, KDR, TEK |
BP | Unclassified; | GO:0044259; multicellular organismal macromolecule metabolic process | 1.560E-04 | 5.701E-03 | HIF1A, MMP13, MMP2, MMP3, MMP9 |
BP | GO:0009987; cellular process | GO:0045595; regulation of cell differentiation | 1.615E-04 | 5.881E-03 | ADRA2C, AKT1, AR, AURKA, AXL, BRAF, CA2, CAMK2B, CDK1, CTDSP1, EGFR, ERBB2, ESRRA, GSK3B, HIF1A, KDR, MAPK1, MAPT, NFKB1, PIK3R1, PTK2, SMAD3, XDH |
BP | GO:0008152; metabolic process | GO:0031324; negative regulation of cellular metabolic process | 1.666E-04 | 6.037E-03 | ADRA2A, AHR, AKT1, APEX1, AR, AURKB, BLM, CDK1, CSNK2A1, CTDSP1, DAPK1, DRD4, DUSP3, ESRRA, GSK3B, HIF1A, HSPA1A, IGF1R, MAPT, MET, MMP3, MMP9, NFKB1, PKN1, PLK1, SMAD3, SRC, STAT6, TP53, USP2, XDH |
BP | GO:0009987; cellular process | GO:0010389; regulation of G2/M transition of mitotic cell cycle | 1.745E-04 | 6.279E-03 | AURKA, AURKB, BLM, CDK1, NEK2, PLK1, PLK4 |
CC | GO:0044464; cell part | GO:0005739; mitochondrion | 1.923E-04 | 6.864E-03 | AKT1, APEX1, BRAF, CA5A, CA5B, CDK1, CYP1A1, CYP1B1, GSK3B, HSD17B10, HSPA1A, MAOA, MAPK1, MMP2, MPO, NFKB1, NOX4, SRC, TP53 |
BP | GO:0022610; biological adhesion | GO:0022407; regulation of cell-cell adhesion | 1.969E-04 | 6.995E-03 | AKT1, ALOX12, ALOX15, BRAF, DUSP3, ERBB2, MAP3K8, PIK3R1, PTK2, SRC |
BP | GO:0065007; biological regulation | GO:0035625; epidermal growth factor-activated receptor transactivation by G-protein coupled receptor signaling pathway | 2.056E-04 | 7.185E-03 | ADRA2A, ADRA2C |
BP | GO:0009987; cellular process | GO:0032811; negative regulation of epinephrine secretion | 2.056E-04 | 7.185E-03 | ADRA2A, ADRA2C |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 2.056E-04 | 7.185E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0005497; androgen binding | 2.056E-04 | 7.185E-03 | ALDH1A1, AR |
BP | GO:0065007; biological regulation | GO:0043393; regulation of protein binding | 2.159E-04 | 7.498E-03 | AURKA, AURKB, GSK3B, MET, MMP9, PLK1, SRC |
BP | GO:0009987; cellular process | GO:0007093; mitotic cell cycle checkpoint | 2.254E-04 | 7.788E-03 | AURKB, BLM, CDK1, PLK1, TP53 |
BP | GO:0009987; cellular process | GO:0051983; regulation of chromosome segregation | 2.489E-04 | 8.469E-03 | AURKB, CSNK2A1, NEK2, NEK6, PLK1 |
BP | GO:0009987; cellular process | GO:2001243; negative regulation of intrinsic apoptotic signaling pathway | 2.489E-04 | 8.469E-03 | AKT1, HIF1A, HSPA1A, MMP9, SRC |
BP | GO:0050896; response to stimulus | GO:0051591; response to cAMP | 2.614E-04 | 8.823E-03 | APEX1, BRAF, NOX4, TEK, TYR |
BP | GO:0032502; developmental process | GO:0002009; morphogenesis of an epithelium | 2.703E-04 | 9.085E-03 | AR, CA2, CA9, EGFR, HIF1A, MET, SMAD3, SRC |
BP | GO:0008152; metabolic process | GO:1902895; positive regulation of pri-miRNA transcription from RNA polymerase II promoter | 2.841E-04 | 9.503E-03 | HIF1A, SMAD3, TP53 |
BP | GO:0008283; cell proliferation | GO:1904707; positive regulation of vascular smooth muscle cell proliferation | 2.841E-04 | 9.503E-03 | HPGD, MMP2, MMP9 |
BP | GO:0002376; immune system process | GO:0002684; positive regulation of immune system process | 2.904E-04 | 9.654E-03 | AKT1, AXL, BRAF, CA2, HIF1A, HSPA1A, MAP3K8, MAPK1, MMP2, NFKB1, PIK3R1, PLA2G1B, PTK2, SRC, STAT6, TP53 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 2.321E-19 | 3.887E-16 | CA1, CA12, CA13, CA14, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, HBB |
MF | GO:0005488; binding | GO:0005524; ATP binding | 4.701E-17 | 3.302E-14 | ABCC1, ABCG2, AKT1, ALK, AURKA, AURKB, AXL, BLM, BRAF, CAMK2B, CDK1, CSNK2A1, DAPK1, EGFR, EPHB4, ERBB2, FLT3, FLT4, GSK3B, HSPA1A, IGF1R, INSR, KDR, MAP3K8, MAPK1, MET, NEK2, NEK6, NUAK1, PDGFRB, PIM1, PKN1, PLK1, PLK4, PTK2, PYGL, RECQL, SRC, TEK, TP53 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 9.802E-17 | 6.278E-14 | CA1, CA12, CA13, CA2, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 9.198E-14 | 2.821E-11 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP2C8, CYP2C9, CYP3A4, HBB, NOX4 |
Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|
hsa00910 | Nitrogen metabolism_Homo sapiens_hsa00910 | 3.916E-24 | 7.480E-22 | CA12; CA1; CA3; CA5B; CA2; CA5A; CA4; CA7; CA6; CA9; CA14; CA13 |
hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 9.784E-14 | 5.105E-12 | PDGFRB; GSK3B; SMAD3; FLT3; DAPK1; MMP2; BRAF; PIK3R1; HIF1A; MMP9; EGFR; NFKB1; PTK2; IGF1R; AR; ERBB2; AKT1; MAPK1; MET; TP53 |
hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 3.769E-14 | 3.599E-12 | CAMK2B; SRC; MMP2; BRAF; PIK3R1; HIF1A; MMP9; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; TP53; MET |
hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 1.069E-13 | 5.105E-12 | PDGFRB; GSK3B; AR; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1; IGF1R |
hsa05219 | Bladder cancer_Homo sapiens_hsa05219 | 1.386E-12 | 5.293E-11 | DAPK1; SRC; MMP2; ERBB2; MAPK1; BRAF; MMP9; TP53; EGFR |
hsa04510 | Focal adhesion_Homo sapiens_hsa04510 | 9.425E-12 | 2.572E-10 | PDGFRB; GSK3B; SRC; FLT4; BRAF; PIK3R1; PTK2; EGFR; IGF1R; ERBB2; KDR; AKT1; MAPK1; MET |
hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 4.575E-12 | 1.456E-10 | PDGFRB; FLT3; ERBB2; AKT1; MAPK1; PIK3R1; TP53; MET; HIF1A; EGFR |
hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.022E-10 | 1.951E-09 | PDGFRB; GSK3B; INSR; FLT4; PIK3R1; PTK2; EGFR; NFKB1; IGF1R; KDR; AKT1; MAPK1; TEK; PKN1; TP53; MET |
hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.622E-11 | 3.873E-10 | CAMK2B; INSR; ERBB2; AKT1; MAPK1; TEK; PIK3R1; HIF1A; EGFR; NFKB1; IGF1R |
hsa05214 | Glioma_Homo sapiens_hsa05214 | 1.128E-10 | 1.959E-09 | PDGFRB; CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; IGF1R |
hsa04012 | ErbB signaling pathway_Homo sapiens_hsa04012 | 6.713E-11 | 1.425E-09 | CAMK2B; GSK3B; SRC; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; EGFR; PTK2 |
hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 1.300E-10 | 2.070E-09 | SMAD3; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1 |
hsa04015 | Rap1 signaling pathway_Homo sapiens_hsa04015 | 2.353E-10 | 3.211E-09 | PDGFRB; SRC; INSR; FLT4; BRAF; PIK3R1; EGFR; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa04014 | Ras signaling pathway_Homo sapiens_hsa04014 | 5.798E-10 | 5.829E-09 | PDGFRB; PLA2G1B; INSR; FLT4; PIK3R1; EGFR; NFKB1; IGF1R; KDR; AKT1; MAPK1; TEK; MET |
hsa05218 | Melanoma_Homo sapiens_hsa05218 | 2.555E-10 | 3.253E-09 | PDGFRB; AKT1; MAPK1; BRAF; PIK3R1; TP53; MET; EGFR; IGF1R |
hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 3.738E-10 | 4.294E-09 | SMAD3; CSNK2A1; SRC; INSR; ERBB2; MAPK1; MET; EGFR; IGF1R |
hsa04913 | Ovarian steroidogenesis_Homo sapiens_hsa04913 | 3.822E-10 | 4.294E-09 | HSD17B1; ALOX5; INSR; HSD17B2; CYP1A1; CYP1B1; CYP19A1; IGF1R |
hsa05213 | Endometrial cancer_Homo sapiens_hsa05213 | 5.306E-10 | 5.631E-09 | GSK3B; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa05223 | Non-small cell lung cancer_Homo sapiens_hsa05223 | 9.829E-10 | 9.387E-09 | ALK; ERBB2; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR |
hsa04068 | FoxO signaling pathway_Homo sapiens_hsa04068 | 4.552E-09 | 4.140E-08 | PLK4; SMAD3; INSR; PLK1; AKT1; MAPK1; BRAF; PIK3R1; EGFR; IGF1R |
hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 1.552E-08 | 1.348E-07 | CYP2C9; CYP2C8; MAOA; ALOX5; ALOX15; MAPK1; BRAF; ALOX12; CYP2C19 |
hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 2.283E-10 | 3.211E-09 | CYP2C9; CYP2C8; PLA2G1B; CYP1A2; ALOX15; CYP3A4; CYP2C19 |
hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 3.392E-08 | 2.816E-07 | FLT3; PIM1; AKT1; MAPK1; BRAF; PIK3R1; NFKB1 |
hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 1.554E-07 | 1.023E-06 | SMAD3; SRC; AKT1; MAPK1; STAT6; PIK3R1; TP53; MMP9; NFKB1 |
hsa04010 | MAPK signaling pathway_Homo sapiens_hsa04010 | 2.360E-07 | 1.454E-06 | PDGFRB; DUSP3; AKT1; MAPK1; BRAF; MAP3K8; MAPT; TP53; EGFR; NFKB1; HSPA1A |
hsa04915 | Estrogen signaling pathway_Homo sapiens_hsa04915 | 9.671E-08 | 6.597E-07 | SRC; MMP2; AKT1; MAPK1; PIK3R1; MMP9; EGFR; HSPA1A |
hsa05202 | Transcriptional misregulation in cancer_Homo sapiens_hsa05202 | 8.234E-08 | 5.825E-07 | HPGD; FLT3; MMP3; TP53; MPO; MMP9; MET; NFKB1; PTK2; IGF1R |
hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 4.250E-07 | 2.437E-06 | PLA2G1B; MAOA; GAA; ALOX15; AKR1B1; ALOX12; PYGL; CYP2C19; CYP3A4; TYR; CYP19A1; HSD17B10; CYP2C9; CYP2C8; FUT7; HSD17B1; ALOX5; HSD17B2; CYP1A2; ALDH1A1; CYP1A1; ALPI; XDH |
hsa05210 | Colorectal cancer_Homo sapiens_hsa05210 | 6.163E-08 | 4.527E-07 | GSK3B; SMAD3; AKT1; MAPK1; BRAF; PIK3R1; TP53 |
hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 6.163E-08 | 4.527E-07 | CYP2C9; CYP2C8; PLA2G1B; ALOX5; ALOX15; ALOX12; CYP2C19 |
hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 1.939E-07 | 1.235E-06 | SMAD3; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1 |
hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 4.299E-07 | 2.437E-06 | CAMK2B; GSK3B; AKT1; MAPK1; BRAF; PIK3R1; TP53; NFKB1 |
hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 1.067E-06 | 5.664E-06 | PDGFRB; ABCC1; ERBB2; PIM1; CYP1B1; MAPK1; TP53; MMP9; MET; EGFR; NFKB1 |
hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 3.839E-08 | 3.055E-07 | HSD17B1; CYP1A2; HSD17B2; CYP1A1; CYP1B1; CYP3A4; CYP19A1 |
hsa04062 | Chemokine signaling pathway_Homo sapiens_hsa04062 | 1.255E-06 | 6.480E-06 | GSK3B; CXCR1; SRC; AKT1; MAPK1; BRAF; PIK3R1; NFKB1; PTK2 |
hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 9.428E-07 | 5.145E-06 | GSK3B; AKT1; MAPK1; BRAF; PIK3R1; TP53; EGFR; NFKB1 |
hsa04933 | AGE-RAGE signaling pathway in diabetic complications_Homo sapiens_hsa04933 | 1.796E-06 | 8.574E-06 | SMAD3; MMP2; PIM1; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04914 | Progesterone-mediated oocyte maturation_Homo sapiens_hsa04914 | 1.465E-06 | 7.173E-06 | PLK1; CDK1; AKT1; MAPK1; BRAF; PIK3R1; IGF1R |
hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 4.338E-07 | 2.437E-06 | CYP2C9; CYP2C8; CYP1A2; CYP1A1; CYP1B1; CYP3A4; CYP2C19 |
hsa04668 | TNF signaling pathway_Homo sapiens_hsa04668 | 3.185E-06 | 1.383E-05 | MMP3; AKT1; MAPK1; MAP3K8; PIK3R1; MMP9; NFKB1 |
hsa04370 | VEGF signaling pathway_Homo sapiens_hsa04370 | 1.292E-06 | 6.495E-06 | SRC; KDR; AKT1; MAPK1; PIK3R1; PTK2 |
hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 5.083E-06 | 2.111E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; TP53; HIF1A |
hsa04114 | Oocyte meiosis_Homo sapiens_hsa04114 | 6.690E-06 | 2.719E-05 | CAMK2B; AR; PLK1; CDK1; MAPK1; AURKA; IGF1R |
hsa05162 | Measles_Homo sapiens_hsa05162 | 1.294E-05 | 5.147E-05 | GSK3B; CSNK2A1; AKT1; PIK3R1; TP53; NFKB1; HSPA1A |
hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.077E-05 | 7.630E-05 | GSK3B; CSNK2A1; CDK1; AKT1; PIK3R1; TP53; NFKB1; HSPA1A |
hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 1.876E-05 | 7.025E-05 | PDGFRB; CXCR1; INSR; AKT1; MAPK1; PIK3R1; EGFR |
hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.491E-05 | 5.813E-05 | GSK3B; INSR; AKT1; MAPK1; BRAF; PIK3R1; PYGL |
hsa04917 | Prolactin signaling pathway_Homo sapiens_hsa04917 | 3.455E-06 | 1.467E-05 | GSK3B; SRC; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 2.066E-06 | 9.395E-06 | AKT1; MAPK1; BRAF; PIK3R1; MET; HIF1A |
hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 1.627E-05 | 6.214E-05 | INSR; AKT1; PIK3R1; TP53; NFKB1; IGF1R |
hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 1.887E-06 | 8.790E-06 | CYP2C9; CYP2C8; CYP1A2; ALDH1A1; CYP1A1; CYP3A4 |
hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 2.688E-06 | 1.194E-05 | CYP2C9; CYP2C8; MAOA; CYP1A2; CYP3A4; CYP2C19 |
hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 2.451E-05 | 8.671E-05 | PDGFRB; AKT1; MAPK1; PIK3R1; HIF1A; EGFR |
hsa04660 | T cell receptor signaling pathway_Homo sapiens_hsa04660 | 2.895E-05 | 1.005E-04 | GSK3B; AKT1; MAPK1; MAP3K8; PIK3R1; NFKB1 |
hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 3.775E-05 | 1.265E-04 | GSK3B; INSR; AKT1; PIK3R1; PYGL; NFKB1 |
hsa04144 | Endocytosis_Homo sapiens_hsa04144 | 1.197E-04 | 3.519E-04 | SMAD3; CXCR1; SRC; KDR; MET; EGFR; HSPA1A; IGF1R |
hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 1.166E-04 | 3.480E-04 | PDGFRB; POLB; GSK3B; SMAD3; AKT1; PIK3R1; TP53; NFKB1 |
hsa05145 | Toxoplasmosis_Homo sapiens_hsa05145 | 5.893E-05 | 1.902E-04 | ALOX5; AKT1; MAPK1; PIK3R1; NFKB1; HSPA1A |
hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 1.516E-04 | 4.259E-04 | LMNA; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 6.473E-05 | 1.994E-04 | ABCC1; AKT1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 1.749E-04 | 4.704E-04 | POLB; SRC; CDK1; MAPK1; PIK3R1; TP53; NFKB1 |
hsa04810 | Regulation of actin cytoskeleton_Homo sapiens_hsa04810 | 2.275E-04 | 6.035E-04 | PDGFRB; SRC; MAPK1; BRAF; PIK3R1; PTK2; EGFR |
hsa04550 | Signaling pathways regulating pluripotency of stem cells_Homo sapiens_hsa04550 | 1.638E-04 | 4.535E-04 | GSK3B; SMAD3; AKT1; MAPK1; PIK3R1; IGF1R |
hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.343E-05 | 8.444E-05 | AKT1; MAPK1; BRAF; PIK3R1; HIF1A |
hsa04022 | cGMP-PKG signaling pathway_Homo sapiens_hsa04022 | 3.927E-04 | 9.869E-04 | INSR; AKT1; MAPK1; PIK3R1; ADRA2C; ADRA2A |
hsa05164 | Influenza A_Homo sapiens_hsa05164 | 5.033E-04 | 1.233E-03 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1; HSPA1A |
hsa04662 | B cell receptor signaling pathway_Homo sapiens_hsa04662 | 6.076E-05 | 1.902E-04 | GSK3B; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa04060 | Cytokine-cytokine receptor interaction_Homo sapiens_hsa04060 | 8.169E-04 | 1.903E-03 | PDGFRB; CXCR1; FLT3; FLT4; KDR; MET; EGFR |
hsa04213 | Longevity regulating pathway - multiple species_Homo sapiens_hsa04213 | 3.212E-05 | 1.096E-04 | INSR; AKT1; PIK3R1; HSPA1A; IGF1R |
hsa04912 | GnRH signaling pathway_Homo sapiens_hsa04912 | 1.734E-04 | 4.704E-04 | CAMK2B; SRC; MMP2; MAPK1; EGFR |
hsa04725 | Cholinergic synapse_Homo sapiens_hsa04725 | 4.367E-04 | 1.083E-03 | CAMK2B; ACHE; AKT1; MAPK1; PIK3R1 |
hsa04620 | Toll-like receptor signaling pathway_Homo sapiens_hsa04620 | 3.532E-04 | 8.994E-04 | AKT1; MAPK1; MAP3K8; PIK3R1; NFKB1 |
hsa05142 | Chagas disease (American trypanosomiasis)_Homo sapiens_hsa05142 | 3.234E-04 | 8.347E-04 | SMAD3; AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 1.328E-04 | 3.844E-04 | AKT1; PIK3R1; TP53; NFKB1; PTK2 |
hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 9.851E-04 | 2.240E-03 | CAMK2B; AKT1; MAPK1; BRAF; PIK3R1; NFKB1 |
hsa04540 | Gap junction_Homo sapiens_hsa04540 | 1.481E-04 | 4.221E-04 | PDGFRB; SRC; CDK1; MAPK1; EGFR |
hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 6.076E-05 | 1.902E-04 | CYP2C9; CYP1A2; CYP1A1; CYP1B1; CYP3A4 |
hsa05120 | Epithelial cell signaling in Helicobacter pylori infection_Homo sapiens_hsa05120 | 4.313E-05 | 1.420E-04 | CXCR1; SRC; MET; EGFR; NFKB1 |
hsa04932 | Non-alcoholic fatty liver disease (NAFLD)_Homo sapiens_hsa04932 | 1.741E-03 | 3.780E-03 | GSK3B; INSR; AKT1; PIK3R1; NFKB1 |
hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.328E-03 | 2.949E-03 | CAMK2B; GSK3B; SMAD3; CSNK2A1; TP53 |
hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 7.235E-04 | 1.727E-03 | GSK3B; SMAD3; PLK1; CDK1; TP53 |
hsa04360 | Axon guidance_Homo sapiens_hsa04360 | 8.060E-04 | 1.901E-03 | GSK3B; MAPK1; MET; PTK2; EPHB4 |
hsa04921 | Oxytocin signaling pathway_Homo sapiens_hsa04921 | 2.123E-03 | 4.556E-03 | CAMK2B; SRC; MAPK1; PIK3R1; EGFR |
hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 8.648E-04 | 1.990E-03 | CAMK2B; GSK3B; MAOA; AKT1; DRD4 |
hsa05152 | Tuberculosis_Homo sapiens_hsa05152 | 3.548E-03 | 7.210E-03 | CAMK2B; SRC; AKT1; MAPK1; NFKB1 |
hsa05010 | Alzheimer's disease_Homo sapiens_hsa05010 | 2.770E-03 | 5.689E-03 | BACE1; GSK3B; MAPK1; MAPT; HSD17B10 |
hsa04611 | Platelet activation_Homo sapiens_hsa04611 | 5.250E-03 | 1.023E-02 | SRC; AKT1; MAPK1; PIK3R1 |
hsa04750 | Inflammatory mediator regulation of TRP channels_Homo sapiens_hsa04750 | 2.396E-03 | 5.085E-03 | CAMK2B; SRC; ALOX12; PIK3R1 |
hsa04916 | Melanogenesis_Homo sapiens_hsa04916 | 2.579E-03 | 5.374E-03 | CAMK2B; GSK3B; MAPK1; TYR |
hsa04261 | Adrenergic signaling in cardiomyocytes_Homo sapiens_hsa04261 | 1.025E-02 | 1.822E-02 | CAMK2B; AKT1; MAPK1; PIK3R1 |
hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 1.279E-02 | 2.221E-02 | PIM1; AKT1; STAT6; PIK3R1 |
hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 2.128E-02 | 3.416E-02 | GPR35; NMUR2; ADRA2C; ADRA2A; DRD4 |
hsa04152 | AMPK signaling pathway_Homo sapiens_hsa04152 | 5.559E-03 | 1.073E-02 | INSR; AKT1; PIK3R1; IGF1R |
hsa04020 | Calcium signaling pathway_Homo sapiens_hsa04020 | 1.969E-02 | 3.215E-02 | PDGFRB; CAMK2B; ERBB2; EGFR |
hsa04670 | Leukocyte transendothelial migration_Homo sapiens_hsa04670 | 4.667E-03 | 9.285E-03 | MMP2; PIK3R1; MMP9; PTK2 |
hsa04380 | Osteoclast differentiation_Homo sapiens_hsa04380 | 6.916E-03 | 1.270E-02 | AKT1; MAPK1; PIK3R1; NFKB1 |
hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 2.153E-02 | 3.426E-02 | CSNK2A1; CDK1; TP53; NFKB1 |
hsa04270 | Vascular smooth muscle contraction_Homo sapiens_hsa04270 | 3.131E-02 | 4.823E-02 | PLA2G1B; MAPK1; BRAF |
hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 2.007E-02 | 3.249E-02 | CAMK2B; AKT1; PYGL |
hsa05146 | Amoebiasis_Homo sapiens_hsa05146 | 1.955E-02 | 3.215E-02 | PIK3R1; NFKB1; PTK2 |
hsa04666 | Fc gamma R-mediated phagocytosis_Homo sapiens_hsa04666 | 1.615E-02 | 2.729E-02 | AKT1; MAPK1; PIK3R1 |
hsa05100 | Bacterial invasion of epithelial cells_Homo sapiens_hsa05100 | 1.032E-03 | 2.320E-03 | SRC; PIK3R1; MET; PTK2 |
hsa05132 | Salmonella infection_Homo sapiens_hsa05132 | 1.310E-02 | 2.255E-02 | MAPK1; PKN1; NFKB1 |
hsa04664 | Fc epsilon RI signaling pathway_Homo sapiens_hsa04664 | 6.907E-03 | 1.270E-02 | AKT1; MAPK1; PIK3R1 |
hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 6.359E-03 | 1.191E-02 | CAMK2B; MAPK1; BRAF |
hsa04976 | Bile secretion_Homo sapiens_hsa04976 | 7.781E-03 | 1.402E-02 | CA2; CYP3A4; ABCG2 |
hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 4.874E-03 | 9.597E-03 | MAPK1; BRAF; IGF1R |
hsa05131 | Shigellosis_Homo sapiens_hsa05131 | 6.095E-03 | 1.153E-02 | SRC; MAPK1; NFKB1 |
hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.014E-03 | 8.070E-03 | INSR; AKT1; PIK3R1 |
hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 6.095E-03 | 1.153E-02 | SMAD3; STAT6; NFKB1 |
hsa05144 | Malaria_Homo sapiens_hsa05144 | 3.182E-02 | 4.824E-02 | HBB; MET |
hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 3.182E-02 | 4.824E-02 | MAOA; NFKB1 |
hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 2.588E-03 | 5.374E-03 | INSR; MAPK1; PIK3R1 |
hsa04973 | Carbohydrate digestion and absorption_Homo sapiens_hsa04973 | 2.719E-02 | 4.256E-02 | AKT1; PIK3R1 |
hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 7.810E-05 | 2.368E-04 | MAOA; CYP1A2; CYP1A1; CYP1B1 |
hsa00983 | Drug metabolism - other enzymes_Homo sapiens_hsa00983 | 2.832E-02 | 4.397E-02 | CYP3A4; XDH |
hsa02010 | ABC transporters_Homo sapiens_hsa02010 | 2.607E-02 | 4.116E-02 | ABCC1; ABCG2 |
hsa04960 | Aldosterone-regulated sodium reabsorption_Homo sapiens_hsa04960 | 1.419E-03 | 3.116E-03 | INSR; MAPK1; PIK3R1 |
hsa05020 | Prion diseases_Homo sapiens_hsa05020 | 1.695E-02 | 2.816E-02 | MAPK1; HSPA1A |
hsa00052 | Galactose metabolism_Homo sapiens_hsa00052 | 1.262E-02 | 2.212E-02 | GAA; AKR1B1 |
hsa05216 | Thyroid cancer_Homo sapiens_hsa05216 | 5.915E-04 | 1.430E-03 | MAPK1; BRAF; TP53 |
hsa00350 | Tyrosine metabolism_Homo sapiens_hsa00350 | 1.695E-02 | 2.816E-02 | MAOA; TYR |
hsa04320 | Dorso-ventral axis formation_Homo sapiens_hsa04320 | 1.030E-02 | 1.822E-02 | MAPK1; EGFR |
hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 1.515E-02 | 2.584E-02 | POLB; APEX1 |
hsa04964 | Proximal tubule bicarbonate reclamation_Homo sapiens_hsa04964 | 7.535E-03 | 1.371E-02 | CA2; CA4 |
hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 3.185E-04 | 8.333E-04 | CYP1A2; XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
---|---|---|---|
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; ALOX5 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | MAOA; ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | AR; ESRRA |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; INSR; PDGFRB; GSK3B |
NA: NA | Male hypogonadism | NA | AR |
C00-D49: Neoplasms | Malignant adrenal gland cancer | C74.0 | IGF1R |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9 |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | INSR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | ADRA2A |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TEK; KDR |
C00-D49: Neoplasms | Myelofibrosis | C94.4, D47.4 | FLT3 |
C00-D49: Neoplasms | Myeloid leukemia | C92 | FLT3 |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | ADRA2C; CA4; CA4 |
C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; AKT1; INSR; HIF1A; EGFR; ERBB2; PLK1 |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR |
A00-B99: Certain infectious and parasitic diseases | Lymphatic filariasis | B74 | ALOX5 |
K00-K95: Diseases of the digestive system | Liver disease | K70-K77 | MET |
C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vascular restinosis following vascular graft surgery | T82.858A | FLT4 |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Male hormonal deficiencies | E20-E35 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | ADRA2C |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR |
K00-K95: Diseases of the digestive system | Crohn's disease | K50 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Cystic fibrosis | E84 | AR |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | EGFR |
I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B; ABCC1; ESRRA; ALOX5; TEK |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B; ESRRA; ALOX5; ALOX5; ERBB2; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Myocardial reperfusion injury | T86.4 | AKT1 |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | MMP3 |
C00-D49: Neoplasms | Liver cancer | C22 | IGF1R; KDR |
C00-D49: Neoplasms | Leukemia | C90-C95 | AKT1; FLT3 |
A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
C00-D49: Neoplasms | Late-stage non-small cell lung cancer | C33-C34 | EPHB4 |
A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA; TYR |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | ERBB2; KDR |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | AR; SRC |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR |
L00-L99: Diseases of the skin and subcutaneous tissue | Melasma | L81.1 | TYR |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR |
C00-D49: Neoplasms | Melanoma | C43 | BRAF; EGFR; TYR; KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | ALOX5 |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; ACHE; ADRA2C; CA1; CA1 |
NA: NA | GIST | NA | FLT3 |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | SRC; EGFR; EGFR; ERBB2 |
C00-D49: Neoplasms | Gliosarcoma | NA | FLT3 |
C00-D49: Neoplasms | Glioma | C71 | EGFR; EGFR; KDR |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Erectile dysfunction | F52.2, N48.4 | DRD4 |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriatic disorder | L40 | IGF1R |
I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | MAOA; MAOA |
C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA |
H00-H59: Diseases of the eye and adnexa | Graves' ophthalmopathy | H06.2 | IGF1R |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Growth failure | R62.8 | IGF1R |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis in post-menopausal women | M80-M81 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1/2 diabetes | E08-E13 | INSR |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1 |
NA: NA | Edema | NA | CA2 |
I00-I99: Diseases of the circulatory system | Edema associated with congestive heart failure | I50, R60.9 | CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH |
E00-E89: Endocrine, nutritional and metabolic diseases | Endocrine disease | E00-E35 | AR |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | EGFR; KDR |
C00-D49: Neoplasms | Metastatic melanoma | C43 | BRAF; BRAF |
C00-D49: Neoplasms | Metastatic prostate cancer | C61 | AR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE |
I00-I99: Diseases of the circulatory system | Stroke | I61-I63, I80-I82 | MMP9 |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MPO; MAOA; ACHE; BRAF |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE |
H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; EGFR; EGFR; EGFR; TP53; KDR; KDR |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | AR; XDH; ADRA2C |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE |
K00-K95: Diseases of the digestive system | Duodenal ulcers | K25-K27 | CA2; CA1 |
C00-D49: Neoplasms | Mesothelioma | C45 | PTK2 |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | AR; KDR |
A00-B99: Certain infectious and parasitic diseases | Human immunodeficiency virus infection | B20-B26 | FLT3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperglycaemia in type 2 diabetes | E11, R73.9 | INSR |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | SRC; AURKB; TP53 |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE |
C00-D49: Neoplasms | Hematologic malignancies | C81-C86 | AKT1 |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | FLT3; IGF1R; MMP9; EGFR; EGFR; ERBB2; TP53; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1 |
C00-D49: Neoplasms | Metastatic HER2-negative gastric cancer | NA | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | ALOX5; MMP13; MMP3; MMP2 |
A00-B99: Certain infectious and parasitic diseases | Fungal infections | B35-B49 | ALOX5 |
C00-D49: Neoplasms | Acute lymphoblastic leukemia | C91.0 | FLT3 |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | AR; IGF1R |
NA: NA | HIV infections | NA | AHR |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1 |
I00-I99: Diseases of the circulatory system | High blood pressure | I10-I16 | CA2 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Contusion | S36.220S | ADRA2C |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hunter syndrome | E76.1 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypercholesterolemia | E78 | INSR |
C00-D49: Neoplasms | Gastric cancer | C16 | EGFR; EGFR; ERBB2; KDR; KDR |
L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | MET |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Fibromyalgia | M79.7 | ADRA2C |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | FLT3; FLT3; AURKB; AURKA; TP53; TP53; PLK1 |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; ADRA2C |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE |
I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | INSR |
I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Erythema | L51-L54 | ADRA2C |
C00-D49: Neoplasms | Female androgenresponsive recurrent mammary cancer | C50 | AR |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR |
I00-I99: Diseases of the circulatory system | Heart disease | I00-I52 | MET |
E00-E89: Endocrine, nutritional and metabolic diseases | Pompe's disease | E74.02 | GAA |
C00-D49: Neoplasms | Prostate cancer | C61 | AR; AR; FLT3; FLT4; EGFR; ERBB2; PLK1 |
K00-K95: Diseases of the digestive system | Peptic ulcer | K25-K27 | ADRA2C |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | PTK2; BRAF; AURKA; TP53 |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA; MAPT; INSR; ACHE; ACHE; ACHE; GSK3B; ADRA2C |
L00-L99: Diseases of the skin and subcutaneous tissue | Alopecia | L65.9 | AR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B; ALOX5 |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | AR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypoglycemia | E16.0-E16.2 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH |
I00-I99: Diseases of the circulatory system | Hypotension | I95 | ADRA2C |
C00-D49: Neoplasms | Ovarian cancer | C56 | MMP2; EGFR; EGFR; KDR; KDR; KDR; KDR |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; KDR |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR |
C00-D49: Neoplasms | Thyroid cancer | C73 | BRAF; KDR |
E00-E89: Endocrine, nutritional and metabolic diseases | Testosterone deficiency | E29.1 | AR |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | ALOX5 |
C00-D49: Neoplasms | Solid tumors | NA | BRAF |
J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | MPO; ALOX5 |
A00-B99: Certain infectious and parasitic diseases | Infections disease | A00-B99 | MPO |
C00-D49: Neoplasms | Advanced breast cancer | C50 | SRC; CYP19A1 |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; ACHE |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
C00-D49: Neoplasms | Cancer | C00-C96 | AR; CA9; AKT1; MET; CSNK2A1; FLT3; FLT3; MMP2; ACHE; SRC; IGF1R; PTK2; BRAF; BRAF; AURKA; FLT4; EPHB4; TEK; GSK3B; HIF1A; CDK1; MAPK1; MMP9; NFKB1; EGFR; ERBB2; ERBB2; PIM1; TP53; CA1; KDR; PLK1 |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | AR; ESRRA |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Muscle atrophy | M62.5 | AR |
C00-D49: Neoplasms | Multiple myeloma | C90 | AHR; SRC; IGF1R |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | MPO |
G00-G99: Diseases of the nervous system G00-G99 | Motor neurone disease | G12.2 | IGF1R |
C00-D49: Neoplasms | Metastasis | C00-C97 | AXL |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B; ESRRA; ADRA2C |
G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | MAOA; ADRA2C |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | AR; KDR |
C00-D49: Neoplasms | Castration-resistant prostate cancer | C61 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | AR; AR; ESRRA; MMP2 |
C00-D49: Neoplasms | Renal cancer | C64 | CA9; KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | MAOA |
S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | ADRA2A |
I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | SRC; TEK |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR |
A00-B99: Certain infectious and parasitic diseases | HCV infection | B17.1, B18.2 | MMP3 |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR |
C00-D49: Neoplasms | Bladder cancer | C67 | AR; CYP19A1; EGFR; ERBB2 |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Beta thalassemia | D56.1 | HBB |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | MAOA; CAMK2B; ACHE; CYP3A4 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; DRD4 |
S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
C00-D49: Neoplasms | Breast cancer | C50 | AR; CA9; INSR; FLT3; FLT3; IGF1R; CYP19A1; CDK1; EGFR; EGFR; EGFR; ERBB2; ERBB2; ERBB2; KDR; KDR; KDR |
S00-T88: Injury, poisoning and certain other consequences of external causes | Brain injury | S09.90 | PDGFRB |
C00-D49: Neoplasms | Brain cancer | C71, D33 | SRC; EGFR; EGFR |
NA: NA | Hematopoietic stem cell transplantation | NA | FLT3 |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | MET; IGF1R; FLT4; KDR |
C00-D49: Neoplasms | HER2-positive urogenital cancer | NA | ERBB2 |
NA: NA | Anaplastic mixed oligoastrocytoma | NA | FLT3 |
J00-J99: Diseases of the respiratory system | Rhinitis | J00, J30, J31.0 | ALOX5 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; PLA2G1B; ESRRA; ALOX5; MMP3; CAMK2B; TYR |
H00-H59: Diseases of the eye and adnexa | Retinal venous occlusion | H34.8 | ERBB2 |
C00-D49: Neoplasms | Osteosarcoma | C40-C41 | SRC; GSK3B |
J00-J99: Diseases of the respiratory system | Airway inflammation | J00-J99 | FLT3 |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | MET; AURKA; PLK1 |
K00-K95: Diseases of the digestive system | Alcoholic hepatitis | K70.1 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | AR; MMP13; INSR; ACHE; IGF1R; CDK1; ADRA2C; ADRA2A |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | ERBB2 |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR |
C00-D49: Neoplasms | Chronic myelogenous leukaemia | C92.1 | SRC |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR |
C00-D49: Neoplasms | AML | NA | FLT3; KDR |
J00-J99: Diseases of the respiratory system | Respiratory disease | J00-J99 | ALOX5 |
I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
C00-D49: Neoplasms | Renal cell carcinoma | NA | MMP2; KDR; KDR |
I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; AKT1; MET; FLT3; MMP2; SRC; IGF1R; PTK2; AURKB; AURKA; FLT4; TEK; PDGFRB; HIF1A; MAPK1; MMP9; EGFR; ERBB2; TP53; KDR; KDR; KDR; PLK1; PLK1 |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9 |
C00-D49: Neoplasms | Pancreatic cancer | C25 | AKT1; FLT3; MMP2; EGFR; KDR; PLK1 |
C00-D49: Neoplasms | CLL | NA | FLT3 |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; ACHE |
C00-D49: Neoplasms | Colon cancer | C50 | FLT3; EGFR |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH |
H00-H59: Diseases of the eye and adnexa | Ocular disease | H00-H59 | ADRA2C |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; CA4; CA2 |
G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD4 |
H00-H59: Diseases of the eye and adnexa | Corneal ulcers | H16.0 | MMP3 |
K00-K95: Diseases of the digestive system | Chemotherapy-induced mucositis | K12.3 | MET |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; CA1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B; ALOX5 |
N00-N99: Diseases of the genitourinary system | Prostate hyperplasia | N40 | AR |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | ALOX5; FLT3; EGFR |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | AR |
G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ADRA2C; NPSR1 |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; ABCC1; ABCC1; XDH |
C00-D49: Neoplasms | Glioblastoma | NA | FLT3 |
I00-I99: Diseases of the circulatory system | Ischemic stroke | I61-I63 | MMP3 |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | INSR |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | INSR; NFKB1 |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR |
C00-D49: Neoplasms | Lung cancer | C33-C34 | MMP2; FLT4; EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1 |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic nephropathy | E11.21 | ADRA2C |
E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | ADRA2C |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | EGFR |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MET; AXL; IGF1R; IGF1R; PDGFRB; EGFR; EGFR; KDR |
C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | ERBB2; PLK1 |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; INSR |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ALOX5 |
L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MPO; PLA2G1B; ALOX5; MMP13 |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CA2 |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE |
NA: NA | Upper abdominal bloating | NA | ACHE |
K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MMP9 |